Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Recruiting2
Active Not Recruiting1
Withdrawn1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04514484Phase 1Active Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04216732Recruiting

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

NCT07259304Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT04106843Phase 2Withdrawn

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Showing all 4 trials

Research Network

Activity Timeline